I. Oh

Small cell lung cancer and other thoracic malignancies

M. Nishimura, Y. Hosomi, M. Shibuya, 2012 .

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

S. Novello, R. Dziadziuszko, J. Wolf, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

1299O_PRPrimary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC)

S. Novello, R. Dziadziuszko, J. Mazières, 2017 .

OA02.07 Phase 3 ALUR Study of Alectinib in Pretreated ALK+ NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses

S. Novello, R. Dziadziuszko, J. Mazières, 2019, Journal of Thoracic Oncology.

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer

R. Dziadziuszko, J. Mazières, K. Trunzer, 2022, ESMO open.

Abstracts from the 4th ImmunoTherapy of Cancer Conference

R. Rees, F. Regnier, A. Trautmann, 2017, Journal of Immunotherapy for Cancer.

Association of Worse Prognosis With an Aberrant Diurnal Cortisol Rhythm in Patients With Advanced Lung Cancer

R. Ahn, J. Choi, S. S. Kim, 2012, Chronobiology international.

1346PCNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK+ NSCLC

S. Novello, R. Dziadziuszko, J. Mazières, 2017 .